Priority Filing Window: Applications filed within 60 days of the April 28, 2026 publication of AG Order No. 6754–2026 receive priority processing (decision within six months under § 1301.13(k)(7)) and conditional operating authority during pendency.
California medical marijuana operators holding a current Department of Cannabis Control (DCC) license with a medicinal (“M”) or dual (“M+A”) designation may apply for federal Drug Enforcement Administration registration as a manufacturer, distributor, or dispenser under the expedited pathway established at 21 C.F.R. § 1301.13(k). Whether your business should apply depends on guidance from the State of California, as well as the license type, the medicinal share of inventory, ownership and premises structure, and downstream considerations including § 280E exposure, interstate-commerce posture, and federal supply-chain readiness.
This page is for California operators evaluating whether to file, how to map a DCC license onto the correct federal registration category, and what the federal compliance lift looks like after registration. Kocot Law is admitted in California, Massachusetts, and New York and represents cannabis operators on the federal side of DEA registration in coordination with California state-program compliance.
California: A dUAL-mARKET sTATE
California is a dual-market state. The DCC issues licenses for both medicinal (“M”) and adult-use (“A”) commercial cannabis activity under the Medicinal and Adult-Use Cannabis Regulation and Safety Act, Cal. Bus. & Prof. Code § 26000 et seq.
The April 2026 federal order rescheduled marijuana to Schedule III only when it is in an FDA-approved drug product or subject to a state medical marijuana license. Adult-use cannabis remains a Schedule I controlled substance under federal law. Hemp under 7 U.S.C. § 1639o remains outside the marijuana definition (with the § 781 redefinition to total THC taking effect November 12, 2026).
For California operators, this creates a specific structural question that operators in medical-only states like Oklahoma do not face: federal Schedule III status follows the medicinal portion of your operation only. The compliance design for a California licensee is fundamentally a problem of separating, documenting, and federally accounting for medicinal activity inside a market that primarily serves adult-use customers.
The federal rule frames the same point in cooperative-federalism terms. Under § 1301.13(k)(2), a valid state medical marijuana license is “conclusive evidence that the applicant is authorized under state law to engage in the activity for which registration is sought.” Under § 1301.13(k)(3), DEA registration automatically suspends if the state medical license is suspended, revoked, or expires. The federal registration cannot exceed the scope of the state license. For California operators, this means the DEA registration tracks the M-designation of the DCC license and only the M-designation.
How California’s Medical Cannabis Program Reached This Point
California’s medical cannabis program is the oldest in the United States. The relevant chain of authority for federal-application purposes:
| Authority | Year | Effect |
|---|---|---|
| Compassionate Use Act (Prop 215) | 1996 | Cal. Health & Safety Code § 11362.5. Created the patient-physician recommendation framework that still anchors the medicinal channel. |
| Medical Marijuana Program (SB 420) | 2003 | H&S § 11362.7–11362.83. Established the voluntary Medical Marijuana Identification Card (MMIC) system administered through county health departments. |
| MCRSA + AUMA → MAUCRSA | 2015–2017 | Cal. Bus. & Prof. Code § 26000 et seq. Created the unified state commercial-cannabis licensing structure. |
| SB 158 | 2021 | Consolidated the Bureau of Cannabis Control, CDFA cultivation licensing, and CDPH manufacturing licensing into the single Department of Cannabis Control at Cal. Gov. Code § 12804. |
| DCC implementing regulations | 2022– | 4 CCR §§ 15000–15999. Single regulatory codification governing all commercial activity. |
| AG Order No. 6754–2026 | April 28, 2026 | Schedule III placement for FDA-approved marijuana drug products and state-medical-licensed marijuana; expedited DEA registration pathway at 21 C.F.R. § 1301.13(k). |
Mapping a California Cannabis License Onto a Federal DEA Registration
Under § 1301.13(k)(1), DEA registration under the medical marijuana pathway is granted in one of three categories: manufacturer, distributor, or dispenser. A single entity may hold multiple registrations. The state license type determines which federal categories apply.
| DCC License | State Activity | Federal Registration Analysis |
|---|---|---|
| Type 1 / 1A / 1B / 1C (Specialty Cottage, Specialty, Specialty Indoor, Specialty Mixed-Light) Cultivation | Cultivation up to defined canopy size | Manufacturer analysis. Article 23 cultivation-area designation required under § 1301.13(k)(6)(iii). |
| Type 2 / 2A / 2B Small Cultivation | Cultivation up to 10,000 sq ft | Manufacturer analysis. Article 23 nominal-price mechanism applies. |
| Type 3 / 3A / 3B Medium Cultivation | Cultivation up to 22,000 sq ft (mixed-light) or 1 acre (outdoor) | Manufacturer analysis. Quota implications under Single Convention. |
| Type 4 Nursery | Plants for propagation | Manufacturer analysis (cultivation-area issues distinct from flower cultivators). |
| Type 5 / 5A / 5B Large Cultivation | Cultivation above 22,000 sq ft / 1 acre | Manufacturer analysis. Highest Single Convention quota exposure. |
| Type 6 Manufacturer — Non-Volatile | Non-volatile extraction, infusion, packaging | Manufacturer analysis. Cultivation-area carve-out generally not applicable. |
| Type 7 Manufacturer — Volatile | Volatile solvent extraction | Manufacturer analysis. |
| Type N / Type P Manufacturer — Infusion / Packaging | Limited manufacturing | Manufacturer analysis. |
| Type 10 Retailer (M, A, or M+A) | Retail dispensing | Dispenser analysis. |
| Type 11 Distributor | Transport, QA, tax collection | Distributor analysis. |
| Type 12 Microbusiness | Cultivation (≤ 10,000 sq ft) + manufacturing (Type 6) + distribution + retail at single premises | Three potential registrations (manufacturer, distributor, dispenser) from one DCC license. |
| Type 13 Self-Distribution Transport | Transport of own product | Distributor analysis. |
The application should not be filed as a generic “cannabis registration.” Each registration sought must tie to the specific licensed activity, the specific licensed premises, and the medicinal portion of the operation.
The Central California Issue: M / A / Dual Designation Bifurcation
The single most important federal-application question for a California operator is the M/A bifurcation problem.
A DCC licensee may hold M-only, A-only, or both designations on a single premises. However, the federal rule only addresses medical marijuana licensees.
Schedule III status under the April 2026 order attaches to marijuana “subject to a state medical marijuana license.” Adult-use marijuana (even though it’s from the same plant, processed in the same facility, on the same premises) remains Schedule I. Three operational consequences follow for California operators:
- Inventory separation. Federally, the medicinal inventory must be identifiable as such. The federal rule, § 1301.13(k)(10), accepts state physical-security requirements but the categorization of which inventory is which must be defensible.
- Patient-facing dispensing records. Section 1301.13(k)(5) accepts a state-law-sufficient certification or document for dispensing, provided it is signed and dated on the day issued, contains the patient’s full name and address, and includes the practitioner’s name, address, and state license number. California medicinal retail sales today are most often made to (i) holders of physician recommendations under H&S § 11362.5, or (ii) MMIC holders under H&S § 11362.71. Many California dispensary records may already satisfy § 1301.13(k)(5), but some recommendation-only sales may not, particularly where the recommending physician’s California Medical Board license number is not captured at the point of sale. Pre-registration record review is essential.
- Adult-use spillover. Any adult-use activity on the registered premises is outside the scope of federal Schedule III protection. For Type 10 M+A retailers, the federal registration covers only the medicinal channel. For Type 12 microbusinesses with M+A designation, the same is true at every link in the supply chain. This is the single biggest unaddressed planning question in California operator strategy.
The Type 12 Microbusiness Multi-Registration Problem
A California Type 12 microbusiness under Cal. Bus. & Prof. Code § 26070(a)(3)(A), authorizes cultivation (limited), manufacturing (Type 6 non-volatile), distribution, and retail at a single premises. For DEA purposes, a Type 12 with a medicinal designation may require three separate DEA registrations — manufacturer (for cultivation and Type 6 manufacturing), distributor (for movement to its own retail counter), and dispenser (for retail dispensing).
Section 1301.13(k)(1)(v) explicitly permits a single entity to hold multiple registration types. But each registration carries its own annual fee: currently $3,699 for manufacturers, $1,850 for distributors, and $888 per three-year cycle for dispensers, and each is subject to separate federal compliance obligations. A microbusiness with M+A designation must decide whether the federal compliance investment for its medicinal channel is justified by the medicinal volume, the § 280E savings on the medicinal portion, and the strategic federal posture.
Cultivation, Article 23, and the Single Convention Quota for California Growers
The federal compliance issue that California cultivators are least prepared for is Article 23 of the Single Convention on Narcotic Drugs, 1961, which the rule implements at 21 C.F.R. § 1301.13(k)(6). California operates the largest legal cannabis cultivation footprint in the United States. Outdoor, mixed-light, and indoor cultivation premises are licensed under DCC regulations 4 CCR §§ 15006–15007, with premises diagrams identifying cultivation areas, processing areas, storage, and waste areas.
Three Article 23 requirements apply to manufacturer registrants under § 1301.13(k)(6):
- Cultivation-area specification. Under § 1301.13(k)(6)(iii), the manufacturer registration “shall specify the areas in which marijuana cultivation is permitted.” For California outdoor cultivators with multi-acre footprints, this means each authorized cultivation area must be mapped to the DEA registration. Existing premises diagrams will be the foundation, but federal applications may require additional specificity.
- Nominal-price purchase-and-resale mechanism. Under § 1301.13(k)(6)(i), each registered manufacturer establishes a nominal price for marijuana crops, DEA purchases the crops at that price, and DEA sells them back to the manufacturer (or related entity) at the same price plus the administrative fee calculated under 21 C.F.R. § 1318.06(a). This satisfies the Single Convention’s requirement that a government agency monopolize the wholesale trade in cannabis. Operationally, this is a paper transaction but it requires registration, fee payment, and recordkeeping. California cultivators have never confronted this requirement before.
- Storage access for DEA inspection. Under § 1301.13(k)(6)(ii), registered manufacturers must store harvested crops in a facility to which DEA maintains access until the nominal-price transaction is complete. DEA has the right to inspect on demand. California operators’ existing METRC-tagged storage and secure-storage compliance is a foundation, but the federal access right is independent of the state regime.
- Quota requirements. Section 1301.13(k) requires the Administrator to consider “the requirements of the Single Convention, including any quota requirement” in evaluating applications. The United States submits annual estimates of cannabis production to the International Narcotics Control Board under Single Convention Article 19. As state-licensed medical marijuana enters the federal Schedule III framework, federal aggregate-quota allocations to individual manufacturers become a live question. California cultivators with the largest canopy could face the most pressure on this front.
METRC and Federal Recordkeeping
The California Cannabis Track-and-Trace system (METRC) tags every plant, package, and transfer under Cal. Bus. & Prof. Code § 26067 and 4 CCR § 15048 et seq. The federal rule, § 1301.13(k)(4), provides that DEA “shall accept state-required reports, records, and forms to the maximum extent permissible” and limits federal recordkeeping under part 1304 to what is “necessary to comply with federal statutory and treaty obligations.”
This language is favorable to California operators but is not self-executing. METRC’s data structure was designed for state regulatory needs, not for federal Single Convention reporting (annual estimates and statistical returns under Articles 19 and 20) or federal biennial inventory under 21 C.F.R. § 1304.11. The practical path:
- METRC data can almost certainly satisfy federal biennial-inventory obligations.
- METRC transfer records can almost certainly satisfy intra-registrant transfer records under 21 C.F.R. § 1304.22.
- METRC may not, on its own, satisfy Single Convention statistical-returns reporting. A separate federal-reporting overlay may be required.
Local Control and the Premises Question
Before DEA registration is on the table, the California operator must have a valid licensed premises. Cal. Bus. & Prof. Code § 26200 expressly authorizes cities and counties to prohibit commercial cannabis activity within their jurisdictions. The DCC will not issue a state license for activity that is locally prohibited, and a federal DEA registration cannot exceed the scope of the state license under § 1301.13(k)(3).
The pre-application checklist therefore begins with local authority (Conditional Use Permit, business license, local cannabis permit, and any zoning verification) before any state or federal filing. For operators considering relocation or expansion ahead of federal registration, the local-permitting timeline is the binding constraint.
Conditional Operating Authority During Pendency
For applications filed within 60 days of the April 28, 2026 publication date (through June 27, 2026), § 1301.13(k)(7) provides that the applicant “may engage in the manufacture, distribution, and/or dispensing of marijuana or products containing marijuana for medical purposes in conformity with a state-issued license during the pendency of the application.” DEA must make every effort to process priority applications within six months.
For California operators, conditional operating authority is meaningful but narrow:
- It protects only activity within the scope of the state-issued license.
- It does not protect adult-use activity on the same premises.
- It does not authorize interstate transfer or any activity outside the state license.
Operators considering the window should also understand what filing achieves and what it does not. Filing within the window provides priority processing and conditional operating authority. Filing after the window remains available, with normal processing timelines and no conditional authority during pendency.
§ 280E and California-Specific Tax Implications
The federal rule’s most economically significant collateral effect is the end of 26 U.S.C. § 280E for state-medical-licensed activity. Section 280E disallows ordinary and necessary business deductions for any business “trafficking in controlled substances . . . in a schedule I or II.” Schedule III placement removes state-licensed medical marijuana from the prohibition prospectively.
For California operators, four points warrant attention:
- Prospective relief only — for now. The AG Order encourages the Secretary of the Treasury “to consider providing retrospective relief from Section 280E liability for taxable years in which a state licensee operated under a state medical marijuana license.” This is encouragement, not regulation. California operators should not plan finances based on retrospective relief that has not been promulgated.
- Bifurcation, again. A California M+A licensee remains subject to § 280E on the adult-use portion of revenue. The required separation of cost-of-goods and operating expense between the medicinal and adult-use channels becomes a tax-accounting matter, not just a compliance one.
- California Revenue and Taxation Code conformity. California historically did not conform to § 280E disallowance for state income tax purposes for personal income tax filers (Rev. & Tax. Code § 17209) and adopted partial conformity for corporations (Rev. & Tax. Code § 24436.1). The state-tax interaction with federal Schedule III placement should be reviewed with tax counsel.
- Tax counsel coordination. Section 280E analysis is tax-counsel work. Kocot Law coordinates the federal-registration eligibility analysis but defers tax matters to retained tax counsel for each operator.
What the Federal Rule Does Not Do
The April 2026 order is significant but limited:
- Does not legalize adult-use cannabis federally. Adult-use marijuana remains Schedule I.
- Does not authorize interstate cannabis transfer. State-line crossings are governed by 21 U.S.C. §§ 951–971 and require import/export permits, which are separately regulated under 21 C.F.R. § 1312.30(b)–(d).
- Does not convert a DCC license into a DEA registration automatically. The federal application must be filed under § 1301.13(k).
- Does not extend Schedule III to bulk marijuana or marijuana extract outside FDA-approved products or state-medical-licensed marijuana. Material outside those two categories remains Schedule I.
- Does not protect activity outside the state license. The federal registration’s scope cannot exceed the state license’s scope.
- Does not exempt registrants from federal labeling requirements categorically. State-law labeling is accepted, but the warning required by 21 U.S.C. § 825(c) must still appear where applicable.
- Does not eliminate 18 U.S.C. § 1001 false-statement exposure. Every federal application is sworn under penalty of federal criminal liability for false statements.
California-Specific FAQs
My DCC license is M+A. Do I need to drop the A designation to apply?
No. A California operator can hold M+A designation and apply for DEA registration covering only the medicinal portion. The federal registration is limited by its terms to the scope of the state medical license. Adult-use activity on the same premises continues under state law without federal Schedule III protection. The operational question is whether the registrant can document the separation between medicinal and adult-use activity to a federal standard.
I’m a Type 12 microbusiness. Do I really need three DEA registrations?
You may, depending on which functions you perform with medicinal product. The cultivation function maps to a manufacturer registration. The internal transfer from cultivation/manufacturing to the retail counter is a distribution function. The retail dispensing is a dispenser function. Under § 1301.13(k)(1)(v), a single entity may hold multiple registrations. The economic question is whether your medicinal volume justifies three registration fees and three sets of federal compliance obligations.
My recommending physicians used verbal recommendations under Prop 215. Are those records sufficient for § 1301.13(k)(5)?
Likely not without supplementation. Section 1301.13(k)(5) requires a written certification or document, dated and signed on the day issued, containing the patient’s full name and address and the practitioner’s name, address, and state license number. Most California medicinal dispensary records capture more than a bare verbal recommendation, but pre-application record review is essential. Sales to MMIC holders under H&S § 11362.71 are typically the cleanest predicate.
Does METRC satisfy DEA inventory recordkeeping?
For biennial inventory under 21 C.F.R. § 1304.11 and intra-registrant transfer records, METRC data will likely be acceptable under the rule’s § 1301.13(k)(4) state-record-acceptance provision. For Single Convention statistical returns under Articles 19 and 20, a separate federal-reporting overlay will likely be required.
My city banned commercial cannabis. Can I still apply?
No. The federal registration cannot exceed the scope of a state license, and the DCC will not issue a state license for activity that is locally prohibited under Cal. Bus. & Prof. Code § 26200. The federal pathway is gated by valid state and local authorization.
If I file in June 2026, will my application be processed by year-end?
Section 1301.13(k)(7) directs the Administrator to “make every effort to process all applications submitted within 60 days of the publication of this regulation in the Federal Register within six months.” That is a directive, not a guarantee. Operators with priority filings should plan for a six- to nine-month decision window and design medical operations to continue under conditional operating authority during pendency.
Does federal registration let me ship medical product to Nevada or Oregon?
No. Interstate transfer of marijuana, including marijuana subject to a state medical marijuana license, requires compliance with 21 U.S.C. §§ 951–971 and 21 C.F.R. § 1312.30(b)–(d), which now include marijuana subject to a state medical marijuana license among the substances requiring an import and export permit. Interstate movement is not authorized by the § 1301.13(k) registration alone.
What if my DCC license is suspended after I register with DEA?
Under § 1301.13(k)(3), the DEA registration automatically suspends upon suspension, revocation, or expiration of the underlying state license. There is no independent federal status that survives loss of the state license. Operators in active DCC enforcement should resolve the state matter before federal registration.
Will § 280E retroactive relief actually happen?
The AG Order encourages Treasury to consider retrospective relief. It does not require it, and no Treasury guidance to that effect has been issued. California operators should plan as if § 280E continues to apply to all pre-rescheduling tax years and consult tax counsel on any pending claims or amended-return strategy.
California Documents to Gather Before Filing
- Current DCC license(s) and all amendments, with M/A designation clearly identified
- DCC premises diagram(s)
- Local jurisdiction Conditional Use Permit, business license, or cannabis permit
- DCC ownership and financial-interest disclosures
- METRC enterprise structure and badge holders
- For Type 1–5 cultivators: cultivation-area mapping, light source identification, and water permits
- For Type 6/7/N/P manufacturers: process flow, extraction equipment, and SOP for medical batches
- For Type 10 retailers: medicinal-channel SOP, MMIC verification procedure, and physician-recommendation intake records
- For Type 11/13 distributors: transport SOP, manifests, and QA records
- For Type 12 microbusinesses: separate documentation for each licensed function and inventory bifurcation plan
- DCC inspection reports, Notices of Violation, and Corrective Action Plans within the prior three years
- Any pending DCC amendment, transfer-of-ownership filing, or change-of-premises application
- Insurance certificates required under Cal. Bus. & Prof. Code § 26051.5
- California Medical Board license numbers for the most-cited recommending physicians in dispensary records (Type 10 only)
Scope of Representation
Kocot Law represents California cannabis operators on the federal side of the DEA registration process and the California-side compliance issues that intersect with it.
- Federal scope: § 1301.13(k) application strategy and preparation; public-interest analysis under 21 U.S.C. § 823(e)–(g); Single Convention quota and reporting analysis; Article 23 cultivation-area, nominal-price, and storage-access compliance; post-registration federal compliance (Parts 1301, 1304, 1312, 1317, and 1318); federal status-change client advisories.
- California-side scope: DCC license-alignment review; M/A bifurcation planning; premises-diagram-to-federal-cultivation-area mapping; METRC reporting overlay; local-authority verification.
- Outside scope, with referral coordination: California tax matters (§ 280E and California Revenue & Taxation Code interactions) are referred to specialist tax counsel. Federal criminal defense matters are handled separately under our criminal practice.
A short eligibility call typically identifies the applicable DEA registration categories, the M/A bifurcation issues to address before filing, the Article 23 implications for cultivators, and the documents .
Attorney Advertising. This page is for general informational purposes only and is not legal advice. Visiting this page or contacting Kocot Law does not create an attorney-client relationship. Past results do not guarantee future outcomes. Kocot Law is admitted in California, Massachusetts, and New York. References to federal statutes and regulations are to the United States Code and the Code of Federal Regulations as in effect on the date of publication; the rule discussed above is AG Order No. 6754–2026, published at 91 Fed. Reg. 22714 (April 28, 2026).
Last updated: May 13, 2026.